Antifungal pharmacodynamics: Latin America's perspective

被引:7
作者
Gonzalez, Javier M. [1 ,2 ]
Rodriguez, Carlos A. [2 ]
Agudelo, Maria [2 ,3 ]
Zuluaga, Andres F. [2 ]
Vesga, Omar [2 ,3 ]
机构
[1] Clin CARDIO VID, Medellin, Colombia
[2] Univ Antioquia, Fac Med, Grp Investigador Problemas Enfermedades Infeccios, Medellin, Colombia
[3] Univ Hosp, Unidad Enfermedades Infecciosas, San Vicente Fdn, Medellin, Colombia
关键词
Antifungal agents; Pharmacology; Pharmacodynamics; Pharmacokinetics; Candidiasis; Aspergillosis; LIPOSOMAL AMPHOTERICIN-B; INVASIVE FUNGAL-INFECTIONS; NEUTROPENIC MURINE MODEL; IN-VIVO; CANDIDA-ALBICANS; LIPID COMPLEX; FLUCONAZOLE PHARMACODYNAMICS; PULMONARY ASPERGILLOSIS; PHARMACOKINETICS; POSACONAZOLE;
D O I
10.1016/j.bjid.2016.09.009
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The current increment of invasive fungal infections and the availability of new broadspectrum antifungal agents has increased the use of these agents by non-expert practitioners, without an impact on mortality. To improve efficacy while minimizing prescription errors and to reduce the high monetary cost to the health systems, the principles of pharmacokinetics (PK) and pharmacodynamics (PD) are necessary. A systematic review of the PD of antifungals agents was performed aiming at the practicing physician without expertise in this field. The initial section of this review focuses on the general concepts of antimicrobial PD. In vitro studies, fungal susceptibility and antifungal serum concentrations are related with different doses and dosing schedules, determining the PD indices and the magnitude required to obtain a specific outcome. Herein the PD of the most used antifungal drug classes in Latin America (polyenes, azoles, and echinocandins) is discussed. (C) 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda.
引用
收藏
页码:79 / 87
页数:9
相关论文
共 80 条
[1]   Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): Combined experience from phase I and phase II studies [J].
Adedoyin, A ;
Bernardo, JF ;
Swenson, CE ;
Bolsack, LE ;
Horwith, G ;
DeWit, S ;
Kelly, E ;
Klasterksy, J ;
Sculier, JP ;
DeValeriola, D ;
Anaissie, E ;
LopezBerestein, G ;
LlanosCuentas, A ;
Boyle, A ;
Branch, RA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2201-2208
[2]   Pharmacodynamics of Amphotericin B Deoxycholate, Amphotericin B Lipid Complex, and Liposomal Amphotericin B against Aspergillus fumigatus [J].
Al-Nakeeb, Zaid ;
Petraitis, Vidmantas ;
Goodwin, Joanne ;
Petraitiene, Ruta ;
Walsh, Thomas J. ;
Hope, William W. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (05) :2735-2745
[3]   Nosocomial Fungal Infections: Epidemiology, Infection Control, and Prevention [J].
Alangaden, George J. .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2011, 25 (01) :201-+
[4]   In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model [J].
Andes, D. ;
Diekema, D. J. ;
Pfaller, M. A. ;
Prince, R. A. ;
Marchillo, K. ;
Ashbeck, J. ;
Hou, J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (02) :539-550
[5]   Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo:: Fluconazole and Candida albicans [J].
Andes, D. ;
ForreSt, A. ;
Lepak, A. ;
Nett, J. ;
Marchillo, K. ;
Lincoln, L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) :2374-2383
[6]   In vivo Fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling [J].
Andes, D. ;
Lepak, A. ;
Nett, J. ;
Lincoln, L. ;
Marchillo, K. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (07) :2384-2394
[7]   Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models [J].
Andes, D ;
Safdar, N ;
Marchillo, K ;
Conklin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) :674-684
[8]   Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model [J].
Andes, D ;
van Ogtrop, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2116-2120
[9]   In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species [J].
Andes, D. ;
Diekema, D. J. ;
Pfaller, M. A. ;
Bohrmuller, J. ;
Marchillo, K. ;
Lepak, A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) :2497-2506
[10]   In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model [J].
Andes, D ;
Marchillo, K ;
Stamstad, T ;
Conklin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3165-3169